What topics does this cannabis study cover?

This study covers research on: Pain, Sleep, Neuroprotection.

Where was this research published?

Published in Cannabis and cannabinoid research on June 16, 2026.

Pain Sleep Neuroprotection

Medical cannabis shows promise for Parkinson's pain, sleep, and urinary symptoms

Exploratory Prospective Study of Self-Titrated Medical Cannabis for Nonmotor Symptoms in Parkinson's Disease.

Cannabis and cannabinoid research • June 16, 2026 • Moderately Relevant

🤖

AI Summary

Researchers conducted an exploratory study examining whether medical cannabis could help manage the non-motor symptoms of Parkinson's disease—such as pain, sleep problems, and urinary dysfunction—that often significantly impact quality of life. Over 3 months, 50 patients with Parkinson's disease self-administered cannabis oil extracts or inflorescence products with varying THC/CBD ratios in a real-world, regulated setting. The study tracked improvements using validated clinical scales measuring pain, sleep, urinary function, and overall quality of life, as well as detailed urinary diaries to assess nighttime bathroom frequency.

The results were encouraging for several key symptoms. Participants experienced statistically significant improvements in overall non-motor symptoms (14.5-point reduction on the NMSS scale), better sleep quality (5.9-point improvement on sleep scales), reduced pain (8.1-point improvement on pain scales), and notably, fewer nighttime bathroom trips (median reduction of 0.5 visits). Quality of life also showed modest improvement. Interestingly, these benefits occurred regardless of whether patients used higher THC or CBD-enriched products, suggesting that the therapeutic effect may involve multiple cannabinoids working together rather than a single compound.

The study was well-tolerated with a 26.5% dropout rate, primarily from loss to follow-up rather than adverse effects, indicating feasibility in real-world clinical practice. However, researchers emphasized that these exploratory findings, while promising, represent only a first step. They called for larger randomized controlled trials with standardized dosing, pharmacokinetic monitoring, and cognitive safety assessments to definitively determine whether medical cannabis is truly effective for Parkinson's non-motor symptoms and to identify optimal dosing strategies for patients.

📄 Original Abstract

Medical cannabis (MC) has emerged as a potential therapy for Parkinson's disease (PD), targeting motor and nonmotor symptoms (NMS), such as pain, sleep disturbance, and urinary dysfunction. Cannabinoid receptors in central and peripheral systems, including the bladder, provide a mechanistic basis for symptom modulation. This study evaluated the feasibility, safety, and preliminary clinical effects of MC on NMS in PD within a real-world, regulated framework. In this single-center, open-label, prospective cohort, 68 patients with PD initiating MC were assessed at baseline and at 3 months using validated scales: the Non-Motor Symptoms Scale (NMSS), King's Parkinson's Disease Pain Scale (KPPS), PD Sleep Scale-2 (PDSS-2), PD Quality-of-Life Questionnaire-8 (PDQ-8), and International Prostate Symptom Score (IPSS), along with 2-day urinary diaries. Participants used either cannabis oil extract or inflorescence products with varying THC/CBD (Δ9-tetrahydrocannabinol/cannabidiol) ratios. Adverse events and withdrawals were recorded. Cannabinoid composition was analyzed via ultra-high-performance liquid chromatography and correlated with clinical outcomes. Fifty participants (mean age 65.6 ± 11.0 years; 68% male) completed follow-up. MC use was associated with improvements in NMSS total (Δ 14.5, p = 0.001), PDSS-2 (Δ 5.9, p < 0.001), KPPS (Δ 8.1, p = 0.004), PDQ-8 (Δ 1.5, p = 0.040), and the NMSS urinary domain (Δ 2.1, p = 0.050). Nighttime urinary frequency decreased (median Δ 0.5, p = 0.016), while daytime parameters were unchanged. No correlations were found between cannabinoid composition or THC/CBD enrichment type and clinical response. The dropout rate was 26.5%, mainly due to loss to follow-up. Short-term, self-titrated MC was feasible and appeared generally well tolerated in this open-label setting, suggesting potential benefits for pain, sleep, and nocturnal urinary frequency in PD. These exploratory findings warrant randomized controlled trials focused on these domains and incorporating standardized dosing, pharmacokinetic monitoring, and predefined cognitive safety assessments to determine efficacy, safety, and optimal dosing.

Paper Type

📄 Research

Publication

Journal: Cannabis and cannabinoid research
Published: June 16, 2026
PMID: 42304702
DOI: 10.1177/25785125261458680

Authors (10)

Omer Anis Center for Urogynecology and Reconstructive Pelvic Surgery, Glickman Urological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Simon Lassman Neurological Department, Movement Disorders Institute, Sheba Medical Center, Ramat Gan, Israel.
Tomer Goldberg Neurological Department, Movement Disorders Institute, Sheba Medical Center, Ramat Gan, Israel.
Adi Saar Neurological Department, Movement Disorders Institute, Sheba Medical Center, Ramat Gan, Israel.
David Meiri Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel.
+5 more authors